Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The PreHevbrio vaccine produces higher antibody levels and offers faster protection.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Robert Califf headed the Food and Drug Administration for 10 months under Obama. Will he manage to implement his ideas this time around?
Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.
The Food and Drug Administration approved the single-pill treatment for children weighing at least 30 pounds.
More than half of the therapies in positive industry-sponsored Phase III trials don’t help people with cancer live longer.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
A system that uses vagus nerve stimulation helps people regain mobility in their hands and arms after an ischemic stroke.
As schools reopen, parents have questions about when COVID-19 vaccines will be available for children under 12.
Full approval could encourage more people to get vaccinated and raises the prospect of off-label use.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Alzheimer’s advocates laud the approval of Aduhelm, but experts raise questions about its effectiveness and cost.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.